Ibrutinib dose modification and effectiveness in Japanese patients with chronic lymphocytic leukemia: a post-hoc analysis of the Orbit study
The Orbit study confirmed safety and effectiveness of ibrutinib in Japanese patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL). This post-hoc analysis evaluated ibrutinib treatment patterns and impact of dose modifications, stratifying patients into three subgroups: (1) continuous full-dose (420 mg/day); (2) initially full-dose then discontinued and restarted; (3) reduced starting dose. Dose modifications after resumption in subgroup 2 were mainly due to adverse events (78.5%), and reduced starting doses in subgroup 3 were mainly due to adverse event concerns (79.7%). In subgroup 3, 89.2% experienced dose modification and 32.3% increased to 420 mg/day. Mean relative dose intensity was higher in subgroup 1 than 2/3 (92.5% vs 73.8%/48.1%). The 36-month progression-free survival (PFS)/overall survival rates were 67.9%/88.3%, 75.9%/89.2%, and 86.0%/86.5%, respectively. Subgroups 1 and 3 mainly included biologically unfavorable diseases and elderly vulnerable patients, respectively. Individualized ibrutinib dosing may be effective in maintaining CLL treatment even in real-world practice.
Authors
- Nobuyuki Aotsuka (ORCID: https://orcid.org/0000-0001-9091-791X)
- Ai Omi (ORCID: https://orcid.org/0000-0001-9391-5661)
- Kazuhiro Shibayama
- Tsuyoshi Muta (ORCID: https://orcid.org/0000-0002-8305-9467)
- Takuro Yoshimura (ORCID: https://orcid.org/0000-0002-9411-4556)
- Shingo Kurahashi (ORCID: https://orcid.org/0009-0001-0838-4905)
- Shuichi Ota (ORCID: https://orcid.org/0000-0002-3631-244X)
- Takahiro Kumode (ORCID: https://orcid.org/0000-0002-4799-5362)
- Hideto Tamura (ORCID: https://orcid.org/0000-0003-1782-4375)
- Yoshihiro Kameoka (ORCID: https://orcid.org/0000-0002-6786-3439)
- Yuma Fujimori (ORCID: https://orcid.org/0009-0004-0863-0522)
- Yosuke Masamoto (ORCID: https://orcid.org/0000-0002-8168-6459)
- Eri Matsuki
- Jun Takizawa (ORCID: https://orcid.org/0009-0000-7125-3927)
- Yasushi Isobe (ORCID: https://orcid.org/0000-0001-8030-6621)
- Hirokazu Nagai (ORCID: https://orcid.org/0009-0005-6438-7931)
- Naoki Takahashi (ORCID: https://orcid.org/0000-0001-7572-5004)
- Kensuke Kojima (ORCID: https://orcid.org/0000-0003-4138-0604)
- Go Yamamoto (ORCID: https://orcid.org/0000-0001-9229-2976)
- Sadao Aoki (ORCID: https://orcid.org/0009-0006-2461-0817)
- Junji Suzumiya
- Kazutaka Ozeki
- Takanori Toyama
Institutions
- Dokkyo University (JP)
- Niigata University of Pharmacy and Medical and Life Sciences (JP)
- University of Kochi (JP)
- Akita University (JP)
- Keio University (JP)
- Konan Kosei Hospital (JP)
- Fukuoka University Hospital (JP)
- Kindai University Hospital (JP)
- Osaka City General Hospital (JP)
- Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (JP)
- University of Tokyo Hospital (JP)
- Sapporo Hokuyu Hospital (JP)
- Saitama International Medical Center (JP)
- Akita Red Cross Hospital (JP)
- Japanese Red Cross Narita Hospital (JP)
- Dokkyo Medical University Saitama Medical Center (JP)
- Toyohashi Municipal Hospital (JP)
- Nagoya Medical Center (JP)
- Johnson & Johnson (Brazil) (BR)
- Toranomon Hospital (JP)
- Miyazaki Prefectural NOBEOKA Hospital (JP)
- Johnson & Johnson K.K. (Japan) (JP)
- Niigata University (JP)
- Kōchi University (JP)
- Nippon Medical School (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- Leukemia & lymphoma/Leukemia and lymphoma
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1080/10428194.2026.2746183
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00